Trilantic North America Makes Growth Investment in SOFIE Biosciences

January 28, 2024

Trilantic North America has made a substantial growth investment in SOFIE Biosciences, a founder-led radiopharmacy and radiopharmaceutical CDMO headquartered in Dulles, Virginia. The SOFIE founding team will retain a meaningful equity stake and continue to lead the business; proceeds will be used to expand capacity and points of presence to improve patient access to radiopharmaceuticals.

Buyers
Trilantic North America
Targets
SOFIE Biosciences
Location
Virginia, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.